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Summary  
 
Background Any benefit of adjuvant interferon α-2b (IFNα-2b) for melanoma may depend on 
dose and duration of treatment. Pegylated interferon α-2b (PEG-IFNα-2b) may facilitate 
prolonged exposure while maintaining tolerability. 
Methods 1256 patients with resected Stage III melanoma were randomised to receive observation 
or PEG-IFNα-2b induction 6 µg/kg/wk for 8 weeks then maintenance 3 µg/kg/wk for an intended 
duration of 5 years. Randomization was stratified for microscopic (N1) vs macroscopic (N2) 
nodal involvement, number of positive nodes, ulceration and tumour thickness. Recurrence-free 
survival (RFS) (primary endpoint), distant-metastasis-free survival (DMFS), and overall survival 
(OS) were analyzed for the intent-to-treat population. 
Results At 3.8 years median follow-up, RFS was reduced by 18% (hazard rate [HR] 0.82; 
P=0.01) in the PEG-IFNα-2b arm compared with observation; the 4-year RFS rate was 45.6% vs 
38.9%. DMFS was improved, but non-significantly (P=0.11). OS was unchanged. In stage III-N1, 
both RFS (HR 0.72, 57.7% vs 45.4%, P=0.01) and DMFS (HR 0.73, 60.5% vs 52.6%, P=0.01) 
were prolonged in the PEG-IFNα-2b arm, whereas in stage III-N2 there was no benefit. Grade 3 
and 4 adverse events occurred in 38% and 9% in the PEG-IFNα-2b arm and 9% and 7% in the 
observation arm. PEG-IFNα-2b was discontinued in 31% because of fatigue (15%), depression 
(6%), hepatotoxicity (10%).  
Interpretation Adjuvant PEG-IFNα-2b for stage III melanoma had a significant sustained impact 
on RFS. For N1 disease the impact was also significant for DMFS. Patients with lower disease 
burden clearly benefited more, consistent with our previous trial EORTC 18952 of IFNα-2b. 
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Introduction 
Interferon (IFN)α-2b is the most investigated agent for adjuvant treatment of 
patients with stage IIb (primary tumor ≥ 4 mm, node-negative) and stage III (any primary 
tumor, node-positive) melanoma, both groups at high risk of recurrence after definitive 
surgery.(1) Results from multiple controlled trials suggest that the role of an induction 
period, the optimum dose and duration for adjuvant interferon α in high-risk melanoma 
remain to be defined.(2;3) Individual trials of high- and intermediate-dose interferon α-2b 
for patients at high risk of melanoma recurrence after resection have been shown to 
improve recurrence-free survival (RFS) without, however, showing consistent effects on 
overall survival (OS) compared with observation alone.(4;5;6;7) Low- and intermediate-
dose regimens with either IFNα-2b or IFNα-2a, while more tolerable for longer periods 
of time, have produced transient improvements in RFS or DMFS, again without a 
significant impact on OS.(7;8;9;10;11) A recent meta-analysis of 13 randomised trials 
estimated the benefit of interferon α for reducing the risk of recurrence or death at 13% 
for RFS (P<0.0001) and the risk of death at 10% for OS (P=0.008), without, however, 
defining the optimum dose or duration of interferon therapy.(12). 
An important contribution to the design of EORTC 18991, was provided by the outcome 
of EORTC trial 18952 trial regarding the differential effects of dose and duration of IFN 
therapy in high-risk melanoma. In trial 18952, 1388 patients were randomised to receive 
a 4-week induction period of 10 million units (MIU) IFN 5 days/week followed by either 
10 million units (MIU) three times weekly for 12 months (intermediate higher dose) or 5 
MIU three times weekly for 24 months (intermediate lower dose), or observation.. The 
lower-dose 25-month regimen resulted in a 19% risk reduction for distant metastasis-free 
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interval (DMFI) (P=0.029, borderline significant), while the intermediate-dose, 13-month 
regimen had no effect on DMFI, suggesting longer duration of treatment with lower 
doses may be more effective than shorter-term therapy at higher doses.(7) 
By enabling prolonged, weekly self-administered adjuvant therapy, pegylated interferon 
α-2b (PEG-IFNα-2b) has the potential to improve the benefit-toxicity balance for patients 
with resected stage III melanoma. Therapy with PEG-IFNα-2b has been shown to 
maintain maximal exposure to interferon α-2b for 48 to 72 hours, with a measurable 
residual trough level,  compared with rapid decline from peak plasma concentrations for 
unpegylated IFNα-2b in patients with chronic hepatitis C, allowing once-weekly rather 
than three-times weekly subcutaneous (sc) injections.(13)  
EORTC 18991 clinical trial here reported is a randomised phase 3 controlled study of 
adjuvant therapy conducted in stage III melanoma, where the efficacy and toxicity of 
PEG-IFNα-2b were compared with observation. The rationale was to provide a self-
administered treatment with prolonged exposure, for maximum of 5 years. The study was 
designed to allow dose reductions to maintain ECOG performance status at a score of 0 
to 1 throughout the course of treatment.  
The study of 1256 patients, was designed to measure an improvement in distant 
metastasis-free survival (DMFS) so that treatment could be continued in the event of 
local or regional relapse. In prior consultation with the European regulatory authorities 
and at the request of the United States Food and Drug Administration, the endpoint was 
revised prior to trial analysis to relapse-free survival (RFS), defined as the length of time 
from randomisation to the first of local regional or distant recurrence of melanoma or 
death of any cause. Secondary endpoints of the study included DMFS, overall survival 
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(OS), and safety. The results reported here are the final analysis, and the planned 10-year 
survival follow-up is ongoing. 
 
Patients 
Patients 18 to 70 years of age with histologically documented stage III melanoma (TxN1-
2M0) were enrolled.(1) The primary cutaneous melanoma must have been completely 
excised with adequate surgical margins and complete regional lymphadenectomy must 
have occurred 70 days or less before randomisation. Patients were required to have 
adequate hepatic, renal, and bone marrow function before enrollment. Exclusion criteria 
for this study included ocular or mucous membrane melanoma, evidence of distant 
metastasis or in-transit metastasis, prior malignancy within the past 5 years (other than 
surgically resected non-melanoma skin cancer or cervical carcinoma in situ), autoimmune 
disease, uncontrolled infections, cardiovascular disease, liver or renal disease, use of 
systemic corticosteroids, and prior systemic therapy for melanoma. All patients provided 
written informed consent before randomisation. The following criteria to defined disease 
sub-stage were used: only microscopic, non-palpable nodal involvement (including those 
staged with sentinel node biopsy) or clinically palpable nodal involvement (synchronous 
with removal of the primary tumor or discovered after prior removal of the primary 
tumor). The protocol was approved by the EORTC protocol review committee and the 
local institutional ethical committees. 
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Study design 
Patients were randomly assigned in a 1:1 ratio to one of 2 groups: pegylated interferon α-
2b treatment for 5 years or observation. Randomisation was performed centrally at the 
EORTC Data Center using minimization techniques.(14;15) Patients were stratified by 
disease substage (N1:microscopic vs N2:clinically palpable lymph nodes), number of 
involved lymph nodes, Breslow thickness of the primary tumor, ulceration of the primary 
tumor (present vs absent vs unknown), sex and center. N1 patients, were almost 
exclusively sentinel node (SN) – positive patients. 
Pegylated interferon α-2b was administered at 6 µg/kg/wk subcutaneously (sc) for 8 
weeks (induction), followed by 3 µg/kg/wk sc (maintenance) for an intended treatment 
duration of 5 years. Stepwise dose adjustments (6 µg/kg/wk to 3, 2, and 1 µg/kg/wk 
during the induction phase and from 3 µg/kg/wk to 2 and 1 µg/kg/wk during the 
maintenance phase) of pegylated interferon α-2b were specified by the study protocol to 
adjust for toxicity and in order to maintain an ECOG performance status of 0 or 1 for 
each patient. Treatments could be interrupted for surgery for local or regional recurrence 
of melanoma, then resumed after surgery. 
 
Efficacy evaluation 
Patients in both arms of the study were evaluated for recurrence and distant metastases 
every 3 months during the first 3 years and every 6 months thereafter. Physical 
examination, chest radiography, computed tomography, and other imaging techniques 
were employed as clinically indicated. Recurrence or metastatic lesions were confirmed 
pathologically. The primary endpoint of the study was recurrence-free survival (RFS), 
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defined as time from randomisation to any local or regional recurrence, distant 
metastasis, or death for any reason. Secondary endpoints included distant metastasis-free 
survival (DMFS), defined as time from randomisation to any distant metastasis or death 
for any reason, and overall survival (OS), defined as time from randomisation to death. 
An Independent Review Committee used a blinded review process to determine the dates 
of events and censoring from individual patient data (= last date of disease evaluation for 
RFS and DMFS). These dates form the basis of the primary analysis. 
 
Toxicity evaluation 
The occurrence of adverse events was evaluated at each follow-up visit by physical 
examination, specific questioning of the patient, and by spontaneous reports. All reported 
adverse events were graded according to the Common Toxicity Criteria version 2·0.(16) 
Hematological and laboratory parameters were evaluated at each visit and also as 
clinically indicated. 
 
 
Statistical analysis 
The sample size was calculated to be at least 1200 patients in order to observe 
approximately 576 distant metastases or deaths. With 576 events the study would have 
approximately 90% power to detect a hazard ratio of 0.76 for DMFS, or a 9.75% 
difference (from 40% to 49.75%) at 4 years.(17) Actuarial curves for RFS, DMFS and 
OS were calculated with the Kaplan-Meier technique and the standard errors (SE) of the 
estimated rates at 4 years from randomisation were obtained via the Greenwood 
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formula.(18) The Cox proportional hazards model was used to obtain the hazard ratio for 
the treatment comparison - event rate in the PEG-IFNα-2b group versus the event rate in 
the observation group - and its 95% confidence interval (CI), adjusted for all factors used 
at randomisation. For subgroup analyses, the treatment comparison was considered to be 
significant at the 1% level, and therefore, the 99% CI of the hazard ratio was computed. 
All efficacy analyses were based on the intent-to-treat population, whereas for toxicity 
analysis only patients who started the treatment/observation allocated by randomisation 
and were documented regarding adverse events were included. 
The cut-off date was 31st of March 2006. The database, located at the EORTC Data 
Center, was frozen in December 2006 and SAS 9.1 software (SAS Institute Inc, Cary, 
NC, USA) has been used for the statistical analyses. 
 
 
 
Results 
Between October 2000 and August 2003, 1256 patients were randomised from 99 
institutions in 17 countries, mainly in Europe. There were 627 patients in the PEG-IFNα-
2b arm and 629 patients in the observation arm (see Appendixes 1 and 2). 
 
Patient characteristics 
The median age of the study population was 50 years, with 11% of patients over 65 years 
(Table 1). Demographics and baseline characteristics were very well balanced across 
both treatment arms. Approximately 40% of patients had microscopic nodal disease and 
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60% had clinically palpable nodal disease. The ECOG performance status was 0 in 84% 
of patients and 1 in 16%.  
 
Treatment feasibility and inclusion in analyses according to CONSORT statement 
Out of 1256 patients, 23 (1.4%) were considered ineligible (9 in PEG-IFNα-2b and 14 in 
observation): 6 due to delays of over 70 days  between surgery and randomisation, 6 
because of incorrect staging, 1 because of additional malignancy, 1 with unacceptable 
concomitant treatment, 4 with abnormal laboratory values, and 5 for other reasons. 
Figure 1 shows the treatment allocation and follow up details by treatment arm. 
The median overall treatment duration was 8 weeks for induction and 15 months for 
maintenance.  At 12 months after randomisation, 311 (50%) subjects randomised to 
treatment were under PEG-IFNα-2b treatment. At 4 years, approximately 22% of patients 
remained in the treatment arm of the study vs 38% in the observation arm.  
 
Efficacy 
Overall treatment results and comparisons 
After a median 3.8 years of follow-up, a total of 696 recurrences or deaths had occurred: 
328 in PEG-IFNα-2b and  368 in observation arm (Table 2). Patients allocated to PEG-
IFNα-2b had their risk of recurrence or death significantly reduced by 18% (hazard ratio 
0.82, 95% confidence interval (CI) 0·71–0·96) as compared with those randomised to 
observation (P=0.01). There was a 6.7% (95% CI 0.6%-12.8%) absolute difference in the 
estimated 4-year rates of RFS: 45.6% in the PEG-IFNα-2b group vs 38.9% in the 
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observation group. Kaplan-Meier analysis showed that the benefit of treatment began 
early and was consistent throughout the study (Figure 2 A). 
Multivariate analysis indicated that treatment comparison adjusted for all stratification 
factors used at randomisation remained significant (P=0.02): hazard ratio 0.84, 95% CI 
(0.73-0.98). 
Results for DMFS in the whole population were consistent with those for RFS without 
reaching statistical significance (Table 2 and Figure 2B). The difference in the median 
time to DMFS was similar to that observed for RFS, at 9 months (44 months in the PEG-
IFNα-2b arm and 36 months in the observation arm). A total of 629 distant metastases or 
deaths occurred: 304 vs 325. There was a 2.8% difference in the 4-year DMFS rates: 
estimated 4-year rates of DMFS were 48.2% and 45.4% for the treatment and 
observation arms, respectively.  
Overall survival was not significantly different (P=0.78) between the 2 treatment groups: 
the estimated 4-year overall survival rate was 56.8% in the PEG-IFNα-2b arm and 55.7% 
in the observation arm (Table 2 and Figure 2C). 
 
Subgroup analysis  
The benefits of treatment with PEG-IFNα-2b are more pronounced in patients with 
earlier Stage III melanoma disease than in those with later stage disease (Table 3 and 
Figure 3). In patients with microscopic nodal disease (N1), a reduction of 27% in the risk 
of recurrence or death (RFS hazard ratio 0.73, 99% CI 0.53–1.02; P=0.016) was observed 
in the PEG-IFNα-2b arm compared with observation and an improvement of 12.3% (99% 
CI -2.6%-27.2%) in the 4-year RFS. Similarly, the risk of distant metastases or death was 
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reduced by 25% (DMFS hazard ratio 0.75, 99% CI 0.52–1.07; P=0.03) and the 4-year 
DMFS rate was improved by 7.9%. The treatment difference in OS is, to date, not 
significant (P=0.43). These results were confirmed by multivariate analyses. In contrast, 
patients with palpable nodal disease (N2) showed non significant or no improvement for 
RFS, DMFS, and OS respectively (Table 3 and Figure 4).  
Similarly patients with tumor involvement limited to one lymph node achieved 
reductions in the risk of recurrence or death with PEG-IFNα-2b treatment (hazard rate 
0.71 99% CI 0.71–0.97; P=0.004), as well as reductions in the risk of distant metastases 
or death (hazard rate 0.73, 99% CI 0.53–1.00; P=0.01), and even in the risk of death 
(hazard ratio 0.83, 99% CI 0.58-1.19), compared with patients with more than one  
involved lymph nodes, for whom such reductions were more limited or not seen at all. 
Kaplan-Meier curves patients with one lymph node involvement showed that the benefit 
of treatment with pegylated interferon α-2b began quite early in the study and was 
maintained throughout the study. The 4-year rate treatment benefit was 11.2% (99% CI 
0.4%-22.0%), 9.5% and 5.8% regarding RFS, DMFS and OS respectively (Table 4). 
In patients with lowest tumor burden (microscopic nodal involvement of only one node), 
194 (PEG-IFNα-2b) vs 188 (observation), the treatment difference was significant for 
RFS (hazard ratio 0.64, 99% CI 0.42-0.98; P=0.006) and DMFS (hazard ratio 0.63, 99% 
CI 0.40-1.00; P=0.009), but not for OS (hazard ratio 0.76, 99% CI 0.44-1.30; p=0.18). 
The estimated improvement in 4-year rates was 14.6% (99% CI -0.1%-29.3%), 11.7% 
and 7.3% respectively for these 3 endpoints (Table 5). 
In the subgroup of patients with any number of microscopic nodal involvement and who 
had an ulceration in the primary tumor the impact of PEG-IFNα-2b was significant or 
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almost significant for the 3 endpoints: for RFS (hazard ratio 0.69, 99% CI 0.43-1.12; 
P=0.05), DMFS (hazard ratio 0.59, 99% CI 0.35-0.98; P=0.006) and OS (hazard ratio 
0.61, 99% CI 0.34-1.10; P=0.03) (Table 5). This was not the case in those with 
microscopic nodal involvement and who had non-ulcerated primary (data not shown). 
 
Toxicity and cause of death: treatment comparison 
Adverse events of any severity that were recorded in more than 4% of patients in the 
PEG-IFNα-2b and observation arms are shown in Table 6. NCI-CTC grade 3 events 
occurred in 239 (38%) of patients in the PEG-IFNα-2b arm and in 58 (9%) of patients in 
the observation arm. Grade 4 events occurred in 58 (9%) of patients in the PEG-IFNα-2b 
arm and in 42 (7%) of patients in the observation arm. A total of 191 (31%) patients in 
the PEG-IFNα-2b group discontinued treatment due to toxicity. Adverse events most 
frequently associated with drug discontinuation included fatigue (25%), depression 
(16%), anorexia (14%), nausea (12%), liver function tests (12%), and pyrexia (10%). 
A total of 525 deaths were reported; 262 in the PEG-IFNα-2b arm and 263 in the 
observation arm. The incidence of the most frequent cause of death, malignant disease, 
was similar in the 2 arms: 249 of 627 (42%) in the pegylated interferon α-2b arm and 244 
of 629 (42%) in the observation arm. Cardiovascular disease was the main cause of death 
for 5 patients (1 patient without previous relapse) in the treatment arm and 3 patients in 
the observation arm and infection was the cause of death for 1 patient in each arm. Other 
causes of death were rare and equally distributed between the 2 arms of the study. 
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Discussion 
A major strength of this EORTC 18991 trial is that, with 1256 patients entered, it is the 
largest Phase 3 study of adjuvant therapy in stage III melanoma to date, that it was 
stratified for biologically important factors such as microscopic low tumor burden vs 
macroscopic high tumour burden, and for ulcerated primaries vs non-ulcerated primaries 
and that it shows a sustained, clinically relevant, statistically significant benefit in PEG-
IFNα-2b treated patients. At 3·8 years median follow-up, it shows an increase in median 
RFS of 9.2 months and an absolute increase in estimated 4-year RFS rate from 38.9% in 
the observation arm to 45.6% in the PEG-IFNα-2b arm. This 6.7% improvement in 4-
year RFS indicates that these results are consistent with an increase of the long-term RFS 
rate for 1 in approximately every 15 patients with high risk cutaneous melanoma if they 
receive adjuvant treatment with PEG-IFNα-2b instead of observation only.  
In addition, analysis of secondary endpoints are supportive, showing encouraging but 
non-significant increases in DMFS. The toxicity profile of PEG-IFNα-2b is acceptable 
over a maximum 5-year duration of treatment. Side effects of interferon α-2b most often 
encountered include fatigue and depression. They are higher early in treatment and do not 
increase as treatment progresses. Patients also attribute less percentage of time to these 
effects as treatment progresses. 
These results also show that the Peg-IFN effect is sustained throughout the 5-year 
treatment period. Our results are also consistent with results from EORTC 18952 of 
adjuvant interferon α-2b in stage IIb and III melanoma.(7) In 18952 subgroups of patients 
with earlier stage disease and/or lower disease burden also experienced a more 
pronounced treatment effect, with greater risk reductions and longer durations of RFS 
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and DMFS. Survival, though as yet immature, appears to trend consistently with RFS and 
DMFS. The subgroup of patients with microscopic nodal involvement represented 
approximately 40% of the our study population, and observation of microscopic nodal 
involvement in stage III disease can be expected to increase significantly, due to 
widespread use of SN biopsy.(19) The safety of this regimen appeared very acceptable 
and favourable compared to that reported over consecutive earlier trials for high-dose 
IFNα-2b which report grade 3-4 fatigue incidence of up to 24%, depression of 10% and 
liver toxicity 29%.(5) By contrast, EORTC 18991 patients report a rate of fatigue grade 
3-4 limited to 15% (grade 4 <1 %), depression grade 3 of 6% (grade 4(<1%)) and liver 
toxicity grade 3 of 10% (grade 4: <1%). Finally, unlike high-dose IFNα-2b the toxicity 
does not tend to increase with increased duration of treatment.  
The data from EORTC study 18991 establishes PEG-IFNα-2b as an option for adjuvant 
treatment of patients with resected high-risk melanoma, especially those with lower nodal 
tumor burden. The aim of adjuvant therapy for high-risk melanoma, as for other major 
cancers, is to provide a tolerable treatment that reduces the risk of relapse for many 
patients and potentially achieves a cure. In our study, as an absolute difference of 12.3% 
in the 4-year RFS was observed, in patients with microscopic nodal disease in resected 
stage III melanoma, PEG-IFNα-2b treatment could be considered in this subgroup, since 
the observation of IFN-mediated efficacy in early stage III disease is fully consistent with 
observations in the EORTC 18952 trial, where stage III patients were also stratified by 
microscopic involvement vs palpable nodal involvement. Moreover these data are fully 
consistent with the impact observed in the French and the Austrian adjuvant trials with 
low dose IFN in non-SN-staged stage II melanoma patients, which showed a clear impact 
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on RFS and some effect on OS in trials where the events were most likely caused by the 
N1 (SN-positive) patient populations.(8;9) Less advanced disease (N1) may differ 
biologically from advanced disease (N2) and it seems to be more sensitive to the effects 
of IFN. Another observation made in the exploratory analyses of subgroups indicated that 
ulcerated primary melanomas seemed to more sensitive to IFN as non-ulcerated 
melanomas. This also points in the direction of biologic differences and needs to be 
explored further. 
A further strength of trial 18991 is the decision to retain an observation only arm 
as the comparator with pegylated interferon. This is well illustrated by the problems 
arising from the recent observation of a detrimental effect of vaccine GM2 in EORTC 
trial 18961 on DMFS and OS leading to early cessation (at the 2nd interim analysis) of the 
trial. This development affects the recent meta analysis of current interferon trials. In this 
meta-analysis (12) the absolute improvement of OS rate was only 3% (95% CI 1%-5%) 
at 5 years, and was based on an analysis including the ECOG 1694 trial, which compared 
high dose IFNα-2b to GM2 vaccination which was stopped early (also at the 2nd interim 
analysis) because of a significant difference in favor of IFN α-2b regarding RFS as well 
as OS.(20) This large trial can no longer be part of the meta-analysis and the results of  
rerunning of the meta analysis should be done, by integrating the 18991 data as well. 
Such meta-analysis will allow to check the consistency of our findings in subgroups. 
Markers of patients likely to respond to interferon are needed, and this trial 18991 
indicates that the combination of low tumour volume and an ulcerated primaty may be 
such a marker. This observation requires confirmation, and also investigation to establish 
its biological basis. In EORTC 18991 we cannot confirm the observation of Gogas and 
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colleagues who reported that patients treated with adjuvant interferon who developed 
auto-antibodies against thyroglobulin, antinuclear factors or cardiolipin had a 
significantly better outcome than patients that did not develop these signs of 
autoimmunity.(21) Neither in this trial 18991 nor in the earlier 18952 did those who 
developed auto-antibodies during the course of the study have, subsequently, a lower risk 
of relapse.(22;23) 
In conclusion the combination of results obtained in this trial 18991 and the earlier 18952 
strongly suggest a beneficial effect of adjuvant interferon therapy for the subpopulation 
of stage III patients who have low tumour volume as evidenced by microscopic only 
nodal disease. Similarly, increased benefit is observed in patients with an ulcerated 
primary tumour. These observations will concentrate interferon administration where it is 
most needed and protect those unlikely to respond from unnecessary toxicity. 
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Appendix 2 
Total number of patients included per country 
Country Total 
Australia 36 
Belgium 68 
Bulgaria 29 
Croatia 31 
Czech Republic 5 
Estonia 5 
France 106 
Germany 103 
Israel 8 
Italy 229 
Poland 28 
Portugal 33 
Slovenia 17 
Spain 35 
Switzerland 44 
The Netherlands 152 
United Kingdom 327 
Total 1256 
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Table 1.  
Demographic and baseline characteristics and stratification factors for randomisation* by 
treatment group 
 PEG-IFNα-2b 
n=627 (100%) 
Observation 
n=629 (100%) 
Sex* (n, %)   
 Female 261 (42) 262 (42) 
 Male 366 (58) 367 (58) 
Age (years)   
 Median (range) 50 (19–70) 50 (18–70) 
 18 to <50 (n, %) 311 (50) 311 (49) 
 50 to <65 (n, %) 252 (40) 238 (38) 
 ≥ 65 (n, %) 64 (10) 80 (13) 
Stage of disease* (n, %)   
 Microscopic nodal disease 271 (43) 272 (43) 
 Clinically palpable nodes 356 (57) 357 (57) 
No. Positive Lymph Nodes* (n, %)   
 1 339 (54) 337 (54) 
 2–4 204 (33) 204 (32) 
 ≥ 5 76 (12) 79 (13) 
 Not evaluable 8 (1) 9 (1) 
Breslow thickness* (n, %)   
 <1.5 mm 145 (23) 142 (23) 
 1.5 to 3.99 mm 267 (43) 270 (43) 
 ≥ 4.0 mm 141 (22) 143 (23) 
 Unknown 74 (12) 74 (12) 
Ulceration of primary* (n, %)   
 No 302 (48) 304 (48) 
 Yes 156 (25) 156 (25) 
 Unknown 169 (27) 169 (27) 
Ulceration of primary** (n, %)   
 No 315 (50) 338 (54) 
 Yes 192 (31) 181 (29) 
 Unknown 120 (19) 110 (18) 
 
**: indicated on case report forms (CRF) 
Abbreviations: PegIFN α-2b, pegylated interferon α-2b 
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Table 2.  
Treatment comparison - pegylated interferon α-2b (n=627) vs observation (n=629) - 
regarding several endpoints: recurrence-free survival (RFS), distant metastasis-free 
survival (DMFS), and overall survival (OS)  
Results are expressed as estimates at 4 years (SE%), estimates of the hazard ratios (95% 
CI) and P-values 
 RFS DMFS OS 
 PEG-IFN α-
2b 
Obs PEG-IFN α-
2b 
Obs PEG-IFN α-
2b 
Obs 
No. of events 328 368 304 325 262 263 
4-year rate (%)  
(SE %)* 
45.6 
(2.2) 
38.9 
(2.2) 
48.2 
(2.2) 
45.4 
(2.3) 
56.8 
(2.2) 
55.7 
(2.1) 
Median* (months) 34.8 25.6 45.5 36.0 NR NR 
HR (95% CI) (**;1) 0.82 (0.71–0.96) 0.88 (0.75–1.03) 0.98 (0.82–1.16) 
P-value(**;1) 0.01 0.11 0.78 
HR (95% CI)(**;2) 0.84 (0.73-0.98) 0.90 (0.77-1.06) 1.00 (0.84-1.18) 
P-value(**;2) 0.02 0.20 0.98 
Treament x stage 
interaction***: 
P-value 
0.34 0.18 0.48 
*: Kaplan-Meier estimates along with standard error (SE) obtained via the Greenwood formula 
** P-value given by the Wald test (via a Cox model) 
***: in a Cox model where treatment, stage and treatment x stage were included 
(1): univariate analysis 
(2): multivariate analysis (Cox model): treatment comparison adjusted for stage, number of 
lymph nodes involved, sex, ulceration, Breslow thickness, as indicated at randomization 
Abbreviations: PegIFN α-2b, pegylated interferon α-2b; Obs, observation; NR, not 
reached; HR, hazard ratio; CI, confidence interval 
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Table 3.  
Treatment comparison regarding recurrence-free survival (RFS), distant metastasis-free 
survival (DMFS) and overall survival (OS) according to stage III (microscopic vs 
palpable nodes) given at randomization 
 
 RFS DMFS OS 
 PEG-IFN α-
2b 
Obs PEG-IFN α-
2b 
Obs PEG-IFN 
α-2b 
Obs 
Microscopic    
Nb. of events 108 137 93 117 73 81 
4-year rates* 57.7 (3.3) 45.4 (3.5) 60.5 (3.6) 52.6 (3.5) 71.0 (3.0) 67.2 (3.2) 
Median (mts) NR 42.6 NR 55.4 NR NR 
HR (99%CI)(**;1) 0.73 (0.53-1.02) 0.75 (0.52-1.07) 0.88 (0.64-1.21) 
P-value(**;1) 0.016 0.03 0.43 
HR (99%CI)(**;2) 0.71 (0.51-1.00) 0.70 (0.49-1.00) 0.82 (0.54-1.25) 
P-value(**;2) 0.01 0.011 0.22 
Clinically 
palpable 
   
Nb. of events 220 231 211 208 189 182 
4-year rates* 36.3 (2.8) 33.9 (2.6) 38.7 (2.8) 39.9 (2.7) 45.8 (2.8) 46.8 (2.8) 
Median (yrs) 18.2 13.4 24 21.5 36 40.3 
HR (99%CI)(**;1) 0.86 (0.68-1.10) 0.94 (0.73-1.21) 1.01 (0.83-1.24) 
P-value(**;1) 0.12 0.53 0.91 
HR (99%CI)(**;2) 0.88 (0.69-1.13) 0.97 (0.75-1.24) 1.04 (0.80-1.36) 
P-value(**;2) 0.18 0.72 0.70 
 
*: Kaplan-Meier estimates along with standard error (SE) obtained via the Greenwood formula 
** P-value given by the Wald test (via a Cox model) 
(1): univariate analysis 
(2): multivariate analysis (Cox model): treatment comparison adjusted for number of positive 
lymph nodes, sex, ulceration, Breslow thickness, as indicated at randomization 
Abbreviations: PegIFN α-2b, pegylated interferon α-2b; Obs, observation; NR, not 
reached; HR, hazard ratio; CI, confidence interval 
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Table 4:  
Treatment comparison regarding recurrence-free survival (RFS), distant metastasis-free 
survival (DMFS) and overall survival (OS) according to number of positive lymph nodes 
given at randomization 
 
 RFS DMFS OS 
 PEG-IFN 
α-2b 
Obs PEG-IFN 
α-2b 
Obs PEG-IFN 
α-2b 
Obs 
1 node    
Nb. of events 129 163 118 146 98 112 
4-year rates* 59.6 (2.9) 48.4 (3.0) 62.4 52.9 69.4 (2.6) 63.6 (3.0) 
Median (mts) NR 44.4 NR 55.4 NR NR 
HR(99%CI)(**;1) 0.71 (0.53-0.97) 0.73 (0.53-1.00) 0.83 (0.58-1.19) 
P-value(**;1) 0.004 0.01 0.18 
HR(99%CI) (**;2) 0.69 (0.51-0.94) 0.70 (0.51-1.00) 0.82 (0.57-1.17) 
P-value(**;2) 0.002 0.005 0.15 
2-4 nodes    
Nb. of events 132 133 122 116 109 94 
4-year rates* 32.8 (3.8) 33.0 (3.6) 35.9 41.7 44.9 (3.7) 52.3 (3.7) 
Median (mts) 18.5 18.7 24 28.4 37.7 53.6 
HR(99%CI)(**;1) 0.94 (0.69-1.29) 1.01 (0.73-1.42) 1.17 (0.81-1.68) 
P-value(**;1) 0.62 0.91 0.26 
5+ nodes    
Nb. of events 61 65 58 56 49 51 
4-year rates* 18.6 (4.5) 15.7 (4.5) 20.3 26.0 34.8 (6.0) 33.0 (5.5) 
Median (mts) 9.1 7.7 11.3 13.1 23.3 24.2 
HR(99%CI)(**;1) 0.96 (0.61-1.53) 1.14 (0.71-1.85) 1.02 (0.61-1.70) 
P-value(**;1) 0.84 0.47 0.93 
 
*: Kaplan-Meier estimates along with standard error (SE) obtained via the Greenwood formula 
** P-value given by the Wald test (via a Cox model) 
(1): univariate analysis 
(2): multivariate analysis (Cox model): treatment comparison adjusted for number of positive 
lymph nodes, sex, ulceration, Breslow thickness, as indicated at randomization 
 
Abbreviations: PegIFN α-2b, pegylated interferon α-2b; Obs, observation; NR, not 
reached; HR, hazard ratio; CI, confidence interval 
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Table 5:  
Treatment comparison regarding recurrence-free survival (RFS), distant metastasis-free 
survival (DMFS) and overall survival (OS). 
Subgroup analysis in stage III-N1 (microscopic) patients with only 1 lymph node positive 
(LN+) or with an ulcerated primary melanoma (as indicated on CRFs) 
 RFS DMFS OS 
 PEG-IFN 
α-2b 
Obs PEG-IFN α-
2b 
Obs PEG-IFN α-
2b 
Obs 
Nb. of LN+ 
1    
Nb. pts/events 194/65 188/87 194/56 188/76 194/42 188/51 
4-year (SE)* 63.8 (3.8) 49.2 (4.2) 66.7 (4.0) 55.0 (4.2) 76.7 (3.3) 69.4 (3.8) 
Median (mts) NR 47.2 NR NR NR NR 
HR(99%CI)(**;1) 0.64 (0.42-0.98) 0.63 (0.40-1.00) 0.76 (0.44-1.30) 
P-value(**;1) 0.006 0.009 0.18 
Ulceration 
Present    
Nb. pts/events 96/53 90/62 96/45 90/59 96/33 90/44 
4-year rates* 43.8 (5.4) 26.8 (5.3) 47.4 (6.1) 30.1 (5.3) 65.0 (5.2) 45.4 (5.9) 
Median (mts) 31.0 18.7 47.4 26.3 NR 42.2 
HR(99%CI)(**;1) 0.69 (0.43-1.12) 0.59 (0.35-0.98) 0.61 (0.34-1.10) 
P-value(**;1) 0.05 0.006 0.03 
*: Kaplan-Meier estimates along with standard error (SE) obtained via the Greenwood formula 
** P-value given by the Wald test (via a Cox model) 
(1): univariate analysis 
 
Abbreviations: PegIFN α-2b, pegylated interferon α-2b; Obs, observation; NR, not 
reached; HR, hazard ratio; CI, confidence interval 
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Table 6.  
Adverse events (all, Grade 3, and Grade 4, in descending order of frequency) occurring in 
4% or more (Grade 3 or 4 in the Pegylated interferon α-2b arm) of patients by treatment 
arm 
n (%) Pegylated interferon α-2b (n=613) Observation (n=613) 
 All Grade 3 Grade 4 All Grade 3 Grade 4 
Any 608 (99) 239 (39) 58 (9) 492 (80) 58 (9) 42 (7) 
Fatigue 574 (94) 89 (15) 8 (1) 252 (41) 7 (1) 0 
Liver function 
test* 
480 (78) 64 (10) 2 (<1) 221 (36) 8 (1) 2 (<1) 
Pyrexia 454 (74) 24 (4) 1 (<1) 53 (9) 0 0 
Headache 426 (69) 24 (4) 0 118 (19) 4 (1) 0 
Myalgia 408 (67) 22 (4) 1 (<1) 140 (23) 3 (<1) 0 
Depression 360 (59) 38 (6) 1 (<1) 153 (25) 2 (<1) 1 (<1) 
 
*: SGOT/SGPT/Bilirubin/alkaline phosphatase 
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Figure 1.  
Flow chart (cf CONSORT statement) 
Assessed for eligibility (n=1256) 
 
  Excluded (n=0) 
  Not meeting inclusion criteria 
(n=23) 
 
Randomised (n=1256) 
  
 
Allocated to 5-yr PEG-IFN α-2b 
(n=627) 
 Allocated to Observation (n=629) 
Started allocated intervention 
(n=608) 
Started allocated intervention 
(n=613) 
Did not receive allocated 
intervention (n=19) 
Did not receive allocated 
intervention (n=16) 
Refusal (n=9) Refusal (n=10) 
Distant metastases (n=5) Distant metastases (n=0) 
Ineligible (n=2) Ineligible (n=2) 
Lost to follow-up (n=0) Lost to follow-up (n=1) 
Other (n=3) Other (n=3) 
 
 
Lost to follow-up (n=0)  Lost to follow-up (n=20) 
Still on-study (n=134)  Still on-study (n=233) 
Discontinued intervention (n=474)  Discontinued intervention (n=360) 
Distant metastases (n=173) Distant metastases (n=274) 
Other* (n=45) Other* (n=56) 
Death other cause (n=3) Death (n=2) 
Toxicity (n=191) Toxicity (n=0) 
Refusal (n=51) Refusal (n=19) 
Ineligible (n=1) Ineligible (n=3) 
5-year PEG-IFN α-2b (n=10) 5-year Observation (n=6) 
 
Analysed (n=627)  Analysed (n=629) 
 
*: generally (± 50%) due to a loco-regional relapse 
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LEGEND OF FIGURES 
 
Figure 2: Overall comparison 
2A.  Relapse-Free Survival according to randomised treatment arm. 
N = Number of patients in each arm 
O = Observed number of relapses (local, regional or distant metastasis) or deaths 
P-value given by the logrank test  
 
2B.  Distant-Metastasis-Free Survival according to randomised treatment arm. 
N = Number of patients in each arm 
O = Observed number of distant metastasis or deaths 
P-value given by the logrank test  
 
2C. Duration of survival according to randomised treatment arm. 
N = Number of patients in each arm 
O = Observed number of deaths (whatever the cause) 
P-value given by the logrank test 
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Figure 2B.  
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Figure 2C.  
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Figure 3: Stage III-N1 (microscopic nodal involvement only) patients 
 
3A.  Relapse-Free Survival according to randomised treatment arm. 
N = Number of patients in each arm 
O = Observed number of relapses (local, regional or distant metastasis) or deaths 
P-value given by the logrank test  
 
3B.  Distant-Metastasis-Free Survival according to randomised treatment arm. 
N = Number of patients in each arm 
O = Observed number of distant metastasis or deaths 
P-value given by the logrank test  
 
3C. Duration of survival according to randomised treatment arm. 
N = Number of patients in each arm 
O = Observed number of deaths (whatever the cause) 
P-value given by the logrank test 
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Figure 3B: 
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Figure 4: Stage III-N2 (palpable nodal involvement) patients 
 
4A.  Relapse-Free Survival according to randomised treatment arm. 
N = Number of patients in each arm 
O = Observed number of relapses (local, regional or distant metastasis) or deaths 
P-value given by the logrank test  
 
4B.  Distant-Metastasis-Free Survival according to randomised treatment arm. 
N = Number of patients in each arm 
O = Observed number of distant metastasis or deaths 
P-value given by the logrank test  
 
4C. Duration of survival according to randomised treatment arm. 
N = Number of patients in each arm 
O = Observed number of deaths (whatever the cause) 
P-value given by the logrank test 
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Figure 4B: 
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